FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2616887559> ?p ?o ?g. }

• W2616887559 endingPage "e0178592" @default.
• W2616887559 startingPage "e0178592" @default.
• W2616887559 abstract "Background Although high dose of antimony is the mainstay for treatment of American cutaneous leishmaniasis (ACL), ongoing major concerns remain over its toxicity. Whether or not low dose antimony regimens provide non-inferior effectiveness and lower toxicity has long been a question of dispute. Methods A single-blind, non-inferiority, randomized controlled trial was conducted comparing high dose with low dose of antimony in subjects with ACL treated at a referral center in Rio de Janeiro, an endemic area of Leishmania (Viannia) braziliensis transmission. The primary outcome was clinical cure at 360 days of follow-up in the modified-intention-to-treat (mITT) and per-protocol (PP) populations. Non-inferiority margin was 15%. Secondary objectives included occurrence of epithelialization, adverse events and drug discontinuations. This study was registered in ClinicalTrials.gov: NCT01301924. Results Overall, 72 patients were randomly assigned to one of the two treatment arms during October 2008 to July 2014. In mITT, clinical cure was observed in 77.8% of subjects in the low dose antimony group and 94.4% in the high dose antimony group after one series of treatment (risk difference 16.7%; 90% CI, 3.7–29.7). The results were confirmed in PP analysis, with 77.8% of subjects with clinical cure in the low dose antimony group and 97.1% in the high dose antimony group (risk difference 19.4%; 90% CI, 7.1–31.7). The upper limit of the confidence interval exceeded the 15% threshold and was also above zero supporting the hypothesis that low dose is inferior to high dose of antimony after one series of treatment. Nevertheless, more major adverse events, a greater number of adverse events and major adverse events per subject, and more drug discontinuations were observed in the high dose antimony group (all p<0.05). Interestingly, of all the subjects who were originally allocated to the low dose antimony group and were followed up after clinical failure, 85.7% achieved cure after a further treatment with local therapy or low dose of antimony. Conclusions Compared with high dose, low dose of antimony was inferior at the pre-specified margin after one series of treatment of ACL, but was associated with a significantly lower toxicity. While high dose of antimony should remain the standard treatment for ACL, low dose antimony treatment might be preferred when toxicity is a primary concern." @default.
• W2616887559 created "2017-06-05" @default.
• W2616887559 creator A5002960819 @default.
• W2616887559 creator A5010200533 @default.
• W2616887559 creator A5012984946 @default.
• W2616887559 creator A5032943826 @default.
• W2616887559 creator A5034430639 @default.
• W2616887559 creator A5039160056 @default.
• W2616887559 creator A5044034992 @default.
• W2616887559 creator A5046381634 @default.
• W2616887559 creator A5054521335 @default.
• W2616887559 creator A5059573347 @default.
• W2616887559 creator A5061996777 @default.
• W2616887559 creator A5063222291 @default.
• W2616887559 creator A5071702744 @default.
• W2616887559 creator A5074980579 @default.
• W2616887559 creator A5088780589 @default.
• W2616887559 creator A5089628686 @default.
• W2616887559 date "2017-05-30" @default.
• W2616887559 modified "2023-09-26" @default.
• W2616887559 title "Low versus high dose of antimony for American cutaneous leishmaniasis: A randomized controlled blind non-inferiority trial in Rio de Janeiro, Brazil" @default.
• W2616887559 cites W1165068039 @default.
• W2616887559 cites W1517487519 @default.
• W2616887559 cites W1586208516 @default.
• W2616887559 cites W1895017226 @default.
• W2616887559 cites W1975745197 @default.
• W2616887559 cites W1992344713 @default.
• W2616887559 cites W2000697440 @default.
• W2616887559 cites W2002838459 @default.
• W2616887559 cites W2005875868 @default.
• W2616887559 cites W2009469065 @default.
• W2616887559 cites W2011083855 @default.
• W2616887559 cites W2015678475 @default.
• W2616887559 cites W2031115115 @default.
• W2616887559 cites W2038206223 @default.
• W2616887559 cites W2047157924 @default.
• W2616887559 cites W2050197274 @default.
• W2616887559 cites W2064889140 @default.
• W2616887559 cites W2069416367 @default.
• W2616887559 cites W2074755706 @default.
• W2616887559 cites W2090961207 @default.
• W2616887559 cites W2093657497 @default.
• W2616887559 cites W2106282299 @default.
• W2616887559 cites W2115041725 @default.
• W2616887559 cites W2120859439 @default.
• W2616887559 cites W2128087619 @default.
• W2616887559 cites W2132788729 @default.
• W2616887559 cites W2139079186 @default.
• W2616887559 cites W2143960230 @default.
• W2616887559 cites W2157252039 @default.
• W2616887559 cites W2169279305 @default.
• W2616887559 cites W2174366185 @default.
• W2616887559 cites W2217750255 @default.
• W2616887559 cites W2325452928 @default.
• W2616887559 cites W2402675389 @default.
• W2616887559 cites W2462506978 @default.
• W2616887559 cites W4248396965 @default.
• W2616887559 cites W4248603546 @default.
• W2616887559 cites W4255943186 @default.
• W2616887559 cites W4298085732 @default.
• W2616887559 doi "https://doi.org/10.1371/journal.pone.0178592" @default.
• W2616887559 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5448803" @default.
• W2616887559 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28558061" @default.
• W2616887559 hasPublicationYear "2017" @default.
• W2616887559 type Work @default.
• W2616887559 sameAs 2616887559 @default.
• W2616887559 citedByCount "22" @default.
• W2616887559 countsByYear W26168875592017 @default.
• W2616887559 countsByYear W26168875592018 @default.
• W2616887559 countsByYear W26168875592019 @default.
• W2616887559 countsByYear W26168875592020 @default.
• W2616887559 countsByYear W26168875592021 @default.
• W2616887559 countsByYear W26168875592022 @default.
• W2616887559 countsByYear W26168875592023 @default.
• W2616887559 crossrefType "journal-article" @default.
• W2616887559 hasAuthorship W2616887559A5002960819 @default.
• W2616887559 hasAuthorship W2616887559A5010200533 @default.
• W2616887559 hasAuthorship W2616887559A5012984946 @default.
• W2616887559 hasAuthorship W2616887559A5032943826 @default.
• W2616887559 hasAuthorship W2616887559A5034430639 @default.
• W2616887559 hasAuthorship W2616887559A5039160056 @default.
• W2616887559 hasAuthorship W2616887559A5044034992 @default.
• W2616887559 hasAuthorship W2616887559A5046381634 @default.
• W2616887559 hasAuthorship W2616887559A5054521335 @default.
• W2616887559 hasAuthorship W2616887559A5059573347 @default.
• W2616887559 hasAuthorship W2616887559A5061996777 @default.
• W2616887559 hasAuthorship W2616887559A5063222291 @default.
• W2616887559 hasAuthorship W2616887559A5071702744 @default.
• W2616887559 hasAuthorship W2616887559A5074980579 @default.
• W2616887559 hasAuthorship W2616887559A5088780589 @default.
• W2616887559 hasAuthorship W2616887559A5089628686 @default.
• W2616887559 hasBestOaLocation W26168875591 @default.
• W2616887559 hasConcept C126322002 @default.
• W2616887559 hasConcept C141071460 @default.
• W2616887559 hasConcept C142724271 @default.
• W2616887559 hasConcept C168563851 @default.
• W2616887559 hasConcept C191897082 @default.
• W2616887559 hasConcept C192562407 @default.

• next